Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$7.47 -1.5%	$7.83	$6.85 ▼ $19.89	$447.78M	-0.08	364,418 shs	262,738 shs
CGTX Cognition Therapeutics	$2.02 +21.0%	$0.68	$0.22 ▼ $2.09	$122.70M	1	8.43 million shs	11.67 million shs
ITOS iTeos Therapeutics	$10.21 +0.8%	$10.12	$4.80 ▼ $18.13	$447.80M	1.49	1.03 million shs	1.27 million shs
TNXP Tonix Pharmaceuticals	$36.05 -1.3%	$41.34	$6.76 ▼ $130.00	$320.22M	1.7	2.22 million shs	1.54 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	-4.65%	+4.26%	+0.66%	-3.68%	-57.42%
CGTX Cognition Therapeutics	+12.08%	+51.82%	+155.35%	+424.66%	+120.32%
ITOS iTeos Therapeutics	+0.20%	+0.30%	-1.27%	+23.24%	-36.25%
TNXP Tonix Pharmaceuticals	-8.83%	-38.87%	-22.13%	+28.94%	-17.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEM Cullinan Therapeutics	1.6968 of 5 stars	3.5	0.0	1.7	1.7	0.6
CGTX Cognition Therapeutics	3.3269 of 5 stars	3.6	4.0	3.3	1.7	0.6
ITOS iTeos Therapeutics	2.5495 of 5 stars	3.1	3.0	1.3	3.3	0.6
TNXP Tonix Pharmaceuticals	2.6717 of 5 stars	3.5	2.0	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	3.00	Buy	$28.60	282.86% Upside
CGTX Cognition Therapeutics	3.25	Buy	$2.83	40.26% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.50	51.81% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	94.17% Upside

Current Analyst Ratings Breakdown

Latest CGTX, CGEM, TNXP, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CGEM Cullinan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$35.00 ➝ $28.00
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
8/7/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
7/21/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$12.00 ➝ $10.50
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/27/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$8.33 per share	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.10 per share	N/A
ITOS iTeos Therapeutics	$35M	12.90	N/A	N/A	$11.17 per share	0.91
TNXP Tonix Pharmaceuticals	$10.09M	31.33	N/A	N/A	$19.17 per share	1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$167.38M	-$3.23	N/A	N/A	N/A	N/A	-36.56%	-34.82%	11/6/2025 (Estimated)
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	N/A
ITOS iTeos Therapeutics	-$134.41M	-$4.67	N/A	N/A	N/A	N/A	-33.26%	-28.16%	N/A
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	N/A

Latest CGTX, CGEM, TNXP, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/7/2025	Q2 2025	CGEM Cullinan Therapeutics	-$0.83	-$1.07	-$0.24	-$1.07	N/A	N/A
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A
8/6/2025	Q2 2025	ITOS iTeos Therapeutics	-$1.12	-$1.51	-$0.39	-$1.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	9.83	9.83
CGTX Cognition Therapeutics	N/A	1.54	1.54
ITOS iTeos Therapeutics	N/A	7.53	7.53
TNXP Tonix Pharmaceuticals	N/A	7.53	7.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
CGTX Cognition Therapeutics	43.35%
ITOS iTeos Therapeutics	97.16%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	7.16%
CGTX Cognition Therapeutics	14.40%
ITOS iTeos Therapeutics	14.20%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	59.07 million	54.84 million	Optionable
CGTX Cognition Therapeutics	20	73.47 million	62.89 million	Not Optionable
ITOS iTeos Therapeutics	90	44.21 million	37.93 million	Optionable
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable

CGTX, CGEM, TNXP, and ITOS Headlines

Recent News About These Companies

SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP

August 20 at 4:39 PM | msn.com

Tonix Pharma Announces FDA Approval of Tonmya

August 19 at 8:22 PM | msn.com

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

August 19 at 12:31 PM | seekingalpha.com

Tonix Pharmaceuticals Reports Q2 2025 Financial Results

August 19 at 10:19 AM | msn.com

FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide

August 18 at 2:29 PM | msn.com

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

August 18 at 2:29 PM | finance.yahoo.com

Tonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA Approval

August 18 at 1:20 PM | gurufocus.com

FDA Approves New Fibromyalgia Drug, Tonix Shares Climb

August 18 at 9:28 AM | msn.com

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

August 18 at 9:28 AM | msn.com

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLC

August 18 at 4:22 AM | marketbeat.com

Noble Financial Has Pessimistic Outlook of TNXP Q3 Earnings

August 17 at 8:27 AM | marketbeat.com

FDA approves first new fibromyalgia treatment in over 15 years

August 16, 2025 | thepharmaletter.comT

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?

August 16, 2025 | marketbeat.com

Tonix Secures Fibromyalgia Approval - What Investors Should Know

August 16, 2025 | seekingalpha.com

Tonix Pharma Gains FDA Approval for Tonmya

August 16, 2025 | msn.com

Noble Financial Has Negative Estimate for TNXP Q3 Earnings

August 16, 2025 | americanbankingnews.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

August 15, 2025 | manilatimes.netM

Tonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of Tonmya

August 15, 2025 | msn.com

Tonix Pharmaceuticals stock halted ahead of FDA approval news

August 15, 2025 | investing.com

Form 8K Tonix Pharmaceuticals Holding Corp For: 15 August

August 15, 2025 | investing.com

Tonix Pharmaceuticals (TNXP) Secures FDA Approval for Fibromyalgia Drug

August 15, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX, CGEM, TNXP, and ITOS Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$7.47 -0.11 (-1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$7.48 +0.01 (+0.13%)

As of 05:14 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Cognition Therapeutics NASDAQ:CGTX

$2.02 +0.35 (+20.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.03 +0.01 (+0.50%)

As of 07:59 PM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

iTeos Therapeutics NASDAQ:ITOS

$10.21 +0.08 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$10.14 -0.07 (-0.64%)

As of 05:46 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Tonix Pharmaceuticals NASDAQ:TNXP

$36.05 -0.48 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$36.17 +0.13 (+0.35%)

As of 07:58 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time